Improvement in sinonasal quality-of-life indicators for pediatric patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor

Int Forum Allergy Rhinol. 2023 Jan;13(1):72-75. doi: 10.1002/alr.23036. Epub 2022 Jun 12.

Authors

Carlos X Castellanos¹, Beth Osterbauer², Steven Hasday³, Thomas G Keens⁴, Jeffrey Koempel^{2

3}, Elisabeth H Ference³

Affiliations

¹ Keck School of Medicine of University of Southern California, Los Angeles, California, USA.
² Department of Otolaryngology - Head and Neck Surgery, Children's Hospital Los Angles, Los Angeles, California, USA.
³ Caruso Department of Otolaryngology - Head & Neck Surgery, Keck Medicine of University of Southern California, Los Angeles, USA.
⁴ Department of Pulmonology, Children's Hospital Los Angeles, Los Angeles, California, USA.

PMID: 35643960
DOI: 10.1002/alr.23036

No abstract available

Keywords: SNOT-22; chronic rhinosinusitis; musocilliary clearance; patient reported outcome measure; pediatric rhinology; quality of life.

MeSH terms

Aminophenols / therapeutic use
Child
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis* / drug therapy
Cystic Fibrosis* / genetics
Drug Combinations
Humans
Mutation
Quality of Life

Substances

elexacaftor
ivacaftor
tezacaftor
Cystic Fibrosis Transmembrane Conductance Regulator
Aminophenols
Drug Combinations